Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

Part of paid clinical trials in Berkeley, California.

Sponsor
University of California, Berkeley
Study ID
NCT06367738
Phase
PHASE1
Status
Recruiting

Conditions

  • Aging

Eligibility Criteria

Sex
ALL
Age
60 Years - 85 Years
Healthy Volunteers
Accepted

Interventions

  • Psilocybin — DRUG
    Psilocybin 1-30 mg

Study Details

Participants in this study will undergo a series of non-invasive tests and activities designed to understand how a single dose of psilocybin might influence cognition and emotional well-being in healthy older adults. After providing written informed consent, eligible participants, aged between 60 and 85, will be randomly assigned to receive a dose of psilocybin ranging from a microdose to a moderate-to-high dose. Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) will be used to assess changes in brain structure, while functional magnetic resonance imaging (fMRI) will be used to quantify changes in functional brain activity.

Key Dates

Start date
Nov 30, 2025
Status verified
Oct 2025
Primary completion
Dec 30, 2026
Completion
Dec 30, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Psilocybin Level 1
    The effects of different doses of psilocybin (1 - 10 mg) will be compared.
  • Experimental: Psilocybin Level 2
    Psilocybin (11 - 20 mg) will be administered.
  • Experimental: Psilocybin Level 3
    Psilocybin (21 - 30 mg) will be administered.

Primary Outcome Measure

MRI measurements of brain structure [ Time Frame: Baseline, week 1, and week 4 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, BerkeleyBerkeleyCalifornia94720
BCSP Research Staff
669-244-2436

Find similar trials in Berkeley, CA

Related Studies